Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

European Journal of Surgical Oncology

Volumn 33, Issue 3, 2007, Pages 266-270

  Goonetilleke, K S ^a   Siriwardena, A K ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

CA 19 9; CA 50; CEA; Pancreatic neoplasm; Serum tumour markers

Indexed keywords

BIOCHEMICAL MARKER; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CA 50 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; SIALYL LCAT N TETRAOSE; SPAN 1 PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ALGORITHM; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER STAGING; CHOLESTASIS; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; JAUNDICE; MEDLINE; META ANALYSIS; PANCREAS CANCER; PANCREAS TUMOR; PATIENT CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

CA-19-9 ANTIGEN; HUMANS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947668471     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.10.004     Document Type: Review

References (58)

1. Niederau C., and Grendell J.H. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 7 (1992) 66-86
2. Louhimo J., Alfthan H., Stenman U.H., and Haglund C. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 66 (2004) 126-131
3. Ni X.G., Bai X.F., Mao Y.L., et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31 (2005) 164-169
4. Jiang X.T., Tao H.Q., and Zou S.C. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 3 (2004) 464-468
5. Molina L.M., Diez M., Cava M.T., et al. Tumor markers in pancreatic cancer: A comparative clinical study between CEA, CA19-9 and CA 50. Int J Biol Markers 5 (1990) 127-132
6. Banfi G., Zerbi A., Pastori S., Parolini D., Di-Carlo V., and Bonini P. Behaviour of tumor markers CA19-9, CA195, CAM 43, CA242, and TPS in the diagnosis and follow up of pancreatic cancer. Clin Chem 39 (1993) 420-423
7. Magnani J.L., Steplewski Z., Koprowski H., and Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43 (1983) 5489-5492
8. Lindholm L., Johansson C., Jansson E.L., Hallberg C., and Nilsson O. An immunometric assay (IRMA) for the CA50 antigen. In: Holmgren J. (Ed). Tumour marker antigens (1985), Studentlitteratur, Lund, Sweden 122
9. Hardt P.D., Ngoumou B.K., Rupp J., Schnell-Kretschmer H., and Kloer H.U. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20 (2000) 4965-4968
10. Schneider J., and Schulze G. Comparison of Tumor M2-Pyruvate Kinase (Tumor M2-PK), Carcinoembryonic Antigen (CEA), Carbohydrate antigens CA19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23 (2003) 5089-5093
11. Nishida K., Sugiura M., Yoshikawa T., and Kondo M. Enzyme immunoassay of pancreatic oncofetal antigen (POA) as marker of pancreatic cancer. Gut 26 (1985) 450-455
12. Ohshio G., Manabe T., Watanabe Y., et al. Comparative studies of DUPAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: Evaluation of the influence of obstructive jaundice. Am J Gastroenterol 85 (1990) 1370-1376
13. Basso D., Meggiato T., Fabris C., et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Eur J Clin Invest 22 (1992) 800-804
14. Pearce S., Thornes H., Carr D., and Tanner A. Diagnostic pitfall; interpretation of CA19-9 concentrations in the presence of hepatic dysfunction. Gut 35 (1994) 707-708
15. Basso D., Fabris C., Meggiato T., et al. Serum levels of CA19-9 and tissue polypeptide antigen (TPS) are related to the presence of a benign extra-hepatic cholestasis. Med Sci Res 17 (1989) 13-14
16. Mann D.V., Edwards R., Ho S., Lau W.Y., and Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26 (2000) 474-479
17. Carpelan-Holmstrom M., Louhimo J., Stenman U.H., Alfthan H., and Haglund C.C.E.A. CA19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22 (2002) 2311-2316
18. Jiang J., Wu C., Deng H., et al. Serum level of TGSF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 10 (2004) 1675-1677
19. Ventrucci M., Cipolla A., Racchini C., Casadei R., Simoni P., and Gullo L. Tumor M2-Pyruvate Kinase, a new metabolic marker for pancreatic cancer. Digest Dis Sci 49 (2004) 1149-1155
20. Saito S., Taguchi K., Nishimura N., et al. Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma. Cancer 72 (1993) 381-388
21. Hayakawa T., Naruse S., Kitagawa M., et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol 25 (1999) 23-29
22. McCarthy M.J., Evans J., Sagar G., and Neoptolemos J.P. Prediction of resectability of pancreatic malignancy by computed tomography. Br J Surg 85 (1998) 320-325
23. Chong M., Freeny P.C., and Schmiedl U.P. Pancreatic arterial anatomy: depiction with dual-phase helical CT. Radiology 208 (1998) 537-542
24. Vedantham S., Lu D.S., Reber H.A., and Kadell B. Small peripancreatic veins: improved assessment in pancreatic cancer patients using thin-section pancreatic phase helical CT. AJR Am J Roentgenol 170 (1998) 377-383
25. Rosch T., Lightdale C., Botet J.F., et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 326 (1992) 1721-1726
26. Howard T.J., Chin A.C., Streib E.W., Kopecky K.K., and Wiebke E.A. Value of helical computed tomography, angiography and endoscopic ultrasound in determining resectability of periampullary carcinoma. Am J Surg 174 (1997) 237-241
27. Mertz H.R., Sechopoulos P., Delbeke D., and Leach S.D. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 52 (2000) 367-371
28. Kiriyama S., Hayakawa T., Kondo T., et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreas cancer. Cancer 65 (1990) 1557-1561
29. Kobayashi T., Kawa S., Tokoo M., et al. Comparative study of CA 50 (time resolved fluoroimmunoassay), Span-1, and CA 19-9 in the diagnosis of pancreatic cancer. Scan J Gastroenterol 26 (1991) 787-797
30. Kuusela P., Haglund C., and Roberts P. Comparison of a new tumour marker CA242 with CA19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 63 (1991) 636-640
31. Parker N., Makin C., Ching C., et al. A new enzyme linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 70 (1992) 1062-1068
32. Rothlin M., Joller H., and Largiader F. CA 242 is a new tumor marker for pancreatic cancer. Cancer 71 (1993) 701-707
33. Malesci A., Montorsi M., Mariani A., et al. Clinical utility of the serum CA19-9 test for diagnosing pancreatic cancer in symptomatic patients: a prospective study. Pancreas 7 (1992) 497-502
34. Rosen A., Linder S., Harmenberg U., and Pegert S. Serum levels of CA 19-9 and CA50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 8 (1993) 160-165
35. Friess H., Buchler M., Auerbach B., et al. CA 494- a new tumor marker for the diagnosis of pancreatic cancer. In J Cancer 53 (1993) 759-763
36. Satake K., and Takeuchi T. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 9 (1994) 720-724
37. Kuno N., Kurimoto K., Fukushima M., et al. Effectiveness of multivariate analysis of tumor markers in diagnosis of pancreatic carcinoma: a prospective study in multiinstitutions. Pancreas 9 (1994) 725-730
38. Haglund C., Lundin J., Kuusela P., and Roberts P. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA19-9, CA 50 and CEA. Br J Cancer 70 (1994) 487-492
39. Kawa S., Tokoo M., Hasabe O., et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer 70 (1994) 481-486
40. Gansauge F., Gansauge S., Parker N., et al. CAM 17.1- a new diagnostic marker in pancreatic cancer. Br J Cancer 74 (1996) 1997-2002
41. Kim H., Kim M., Myung S., et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gatroenterol 94 (1999) 1941-1946
42. Slesak B., Harlozinska-Szmyrka A., Knast W., Sedlaczek P., Dalen A., and Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. Cancer 89 (2000) 83-88
43. Nazli O., Bozdag A., Tansug T., Kir R., and Kaymak E. The diagnostic importance of CEA and CA19-9 for the early diagnosis of pancreatic carcinoma. Hepatogatroenterology 47 (2000) 1750-1752
44. Ozkan H., Kaya M., and Cengiz A. Comparison of tumor marker CA242 with CA19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 50 (2003) 1669-1674
45. Pasanen P., Eskelinen M., Partanen K., Pikkarainen P., Pentilla I., and Alhava E. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Br J Cancer 65 (1992) 731-734
46. Nilsson O., Johansson C., Glimelius B., et al. Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA 50 and CA19-9. Br J Cancer 65 (1992) 215-221
47. Palsson B., Masson P., and Andren-Sandberg A. The influence of cholestasis on CA50 and CA242 in pancreatic cancer and benign biliopancreatic diseases. Scan J Gastroenterol 28 (1993) 981-987
48. Andicoechea A., Vizoso F., Alexandre E., et al. Comparative study of Carbohydrate antigen 195 and Carcinoembryonic antigen for the diagnosis of pancreatic carcinoma. World J Surg 23 (1999) 227-232
49. Ritts Jr. E., Nagorney D., Jacobsen D., Talbot R., and Zurawski Jr. V. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 9 (1994) 707-716
50. Cerwenka H., Aigner R., Bacher H., et al. Tu M2-PK (Pyruvate kinase type tumour M2), CA 19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res. 19 (1999) 849-852
51. Hardt P.D., Ngoumou B.K., Rupp J., Schnell-Kretschemer H., and Kloer H.U. Tumour M2-Pyruate kinase: a promising tumour marker in the diagnosis of gastrointestinal cancer. Anticancer Res 20 (2000) 4965-4968
52. Schneider J., and Schulze G. Comparison of tumour M2-pyruvate kinase (Tumour M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigen CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 23 (2003) 5089-5094
53. Schulze G. The tumour marker Tumour M2-PK: an application in the diagnosis of gastrointestinal cancer. Anticancer Res 20 (2000) 4961-4964
54. Oremek G.M., Eigenbrodt E., Rädle J., Zeuzem S.T., and Seiffert U.B. Value of the serum levels of the Tumour marker Tu M2-PK in pancreatic cancer. Anticancer Res. 17 (1997) 3031-3034
55. Siriwardana H.P.P., King N.K.K., France M.W., and Siriwardena A.K. Plasma tumour-M2-pyruvate kinase and serum carbohydrate antigen for the preoperative diagnosis of pancreatic cancer. Br J Surg 92 (2005) 99-101 (abstract)
56. Satake K., Takeuchi T., Homma T., and Ozaki H. CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 9 (1994) 703-706
57. Kim J., Lee K.T., Lee J.K., Paik S.W., Rhee J.C., and Choi K.W. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19 (2004) 182-186
58. Homma T., and Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol 9 (1991) 119-124